Effect of Melatonin on Reversing Multidrug Resistance by Targeting Phosphatase and Tensin Homolog in Leukemia Cancer Cells

Versions

Keywords

Doxorubicin
Leukemia
Melatonin
PTEN

Categories

How to Cite

Rameshknia, V. ., Movahhedi, M. ., Akhavan, A. ., Majidinia, M. ., & Yousefi, B. (2021). Effect of Melatonin on Reversing Multidrug Resistance by Targeting Phosphatase and Tensin Homolog in Leukemia Cancer Cells. Iranian Red Crescent Medical Journal, 23(7). https://doi.org/10.32592/ircmj.2021.23.7.212

Abstract

Background: Recently, melatonin has attracted massive attention due to its anticancer effect on various human malignancies. It has also been demonstrated that melatonin is useful in combating resistance against conventional chemotherapeutics. Objective: This study aimed to evaluate melatonin’s effects on multidrug resistance (MDR) in human myelogenous leukemia cells. Methods: Melatonin’s cytotoxicity on the K562 and K562/doxorubicin (DOX) cell lines was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The expression and activity of P-glycoprotein (P-gp) were measured as well. The mRNA and protein expression levels of tensin homolog deleted on chromosome ten (PTEN) was assessed in cells. Eventually, apoptosis in cancer cells was measured through Annexin V/PI staining. Results: Treatment with melatonin significantly increased the cytotoxicity of DOX on resistant K562 cells. The expression and activity of P-gp were attenuated following melatonin treatment. In addition, melatonin upregulated PTEN in K562/DOX cells. Melatonin also augmented apoptosis in combination with DOX. Conclusion: Melatonin effectively increased the cytotoxic effects of DOX in K562/DOX cells through down-regulation of P-gp and up-regulation of PTEN in resistant K562 cells.
https://doi.org/10.32592/ircmj.2021.23.7.212

References

  1. Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, et al. Overcoming multidrug resistance in cancer: recent progress in nanotechnology and new horizons. IUBMB Life. 2020;72(5):855-71. doi: 10.1002/iub.2215. [PubMed: 31913572].
  2. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. doi: 10.1038/s41586-019-1730-1. [PubMed: 31723286].
  3. Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937-45. doi: 10.2147/ott.s191621. [PubMed: 30881045].
  4. Syed SB, Arya H, Fu IH, Yeh TK, Periyasamy L, Hsieh HP, et al. Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep. 2017;7(1):7972. doi: 10.1038/s41598-017-08062-2. [PubMed: 28801675].
  5. Chatterjee N, Bivona TG. Polytherapy and targeted cancer drug resistance. Trends Cancer. 2019;5(3):170-82. doi: 10.1016/j.trecan.2019.02.003. [PubMed: 30898264].
  6. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. doi: 10.1186/s12943-019-0954-x. [PubMed: 30782187].
  7. Li Y, Guo Y, Feng Z, Bergan R, Li B, Qin Y, et al. Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR Cells. Nutr Cancer. 2019;71(6):1007-18. doi: 10.1080/01635581.2019.1578387. [PubMed: 31032633].
  8. Shi X, Valizadeh A, Mir SM, Asemi Z, Karimian A, Majidina M, et al. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880:173138. doi: 10.1016/j.ejphar.2020.173138. [PubMed: 32416187].
  9. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515-24. doi: 10.1007/s10555-016-9637-x. [PubMed: 27896521].
  10. Chu S, Liu G, Xia P, Chen G, Shi F, Yi T, et al. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep. 2017;38(4):2401-7. doi: 10.3892/or.2017.5859. [PubMed: 28765915].
  11. Najafi M, Salehi E, Farhood B, Nashtaei MS, Hashemi Goradel N, Khanlarkhani N, et al. Adjuvant chemotherapy with melatonin for targeting human cancers: a review. J Cell Physiol. 2019;234(3):2356-72. doi: 10.1002/jcp.27259. [PubMed: 30192001].
  12. Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget. 2017;8(5):8574-89. doi: 10.18632/oncotarget.14351. [PubMed: 28051999].
  13. Talib WH. Melatonin and cancer hallmarks. Molecules. 2018;23(3):518. doi: 10.3390/molecules23030518. [PubMed: 29495398].
  14. Asghari MH, Ghobadi E, Moloudizargari M, Fallah M, Abdollahi M. Does the use of melatonin overcome drug resistance in cancer chemotherapy? Life Sci. 2018;196:143-55. doi: 10.1016/j.lfs.2018.01.024. [PubMed: 29374563].
  15. Yousefi B, Azimi A, Majidinia M, Shafiei-Irannejad V, Badalzadeh R, Baradaran B, et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells. Tumour Biol. 2017;39(10):1010428317716501. doi: 10.1177/1010428317716501. [PubMed: 28978268].
  16. Mashayekhi S, Yousefi B, Tohidi E, Darband SG, Mirza-Aghazadeh-Attari M, Sadighparvar S, et al. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment. J Cell Biochem. 2019;120(9):15719-29. doi: 10.1002/jcb.28841. [PubMed: 31087712].
  17. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15. doi: 10.1038/nature10166. [PubMed: 21720365].
  18. Fic M, Gomulkiewicz A, Grzegrzolka J, Podhorska-Okolow M, Zabel M, Dziegiel P, et al. The impact of melatonin on colon cancer cells' resistance to doxorubicin in an in vitro study. Int J Mol Sci. 2017;18(7):1396. doi: 10.3390/ijms18071396. [PubMed: 28788434].
  19. Liu K, Song J, Yan Y, Zou K, Che Y, Wang B, et al. Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway. Transl Oncol. 2021;14(1):100876. doi: 10.1016/j.tranon.2020.100876. [PubMed: 33007707].
  20. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4):387-90. doi: 10.1016/s0092-8674(00)80674-1. [PubMed: 10693755].
  21. Tang YA, Chen CH, Sun HS, Cheng CP, Tseng VS, Hsu HS, et al. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res. 2015;43(3):1593-608. doi: 10.1093/nar/gkv024. [PubMed: 25609695].
  22. Retracted: MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. Cell Biol Int. 2018;42(10):1455. doi: 10.1002/cbin.10506. [PubMed: 26109338].
  23. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 2008;27(29):4086-95. doi: 10.1038/onc.2008.49. [PubMed: 18332865].
  24. Fang L, Li H, Wang L, Hu J, Jin T, Wang J, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014;5(10):2974-87. doi: 10.18632/oncotarget.1614. [PubMed: 24912422].
  25. Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017;36(1):19. doi: 10.1186/s13046-016-0487-8. [PubMed: 28126034].
  26. Chen J, Zhou C, Li J, Xiang X, Zhang L, Deng J, et al. miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med. 2018;41(4):1855-66. doi: 10.3892/ijmm.2018.3405. [PubMed: 29393355].
  27. Fan L, Sun G, Ma T, Zhong F, Lei Y, Li X, et al. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin. J Pineal Res. 2013;55(2):184-94. doi: 10.1111/jpi.12061. [PubMed: 23711089].
  28. Fan L, Sun G, Ma T, Zhong F, Wei W. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. J Pineal Res. 2013;55(2):174-83. doi: 10.1111/jpi.12060. [PubMed: 23679681].
  29. Yamanishi M, Narazaki H, Asano T. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase. Exp Hematol. 2015;43(3):207-14. doi: 10.1016/j.exphem.2014.11.001. [PubMed: 25461250].